Skip to main content

Table 1 Clinical characteristics and treatments according to the type of cancer

From: Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study

  Uterine cervix Uterine endometrium Tube Ovary Vagina P-value
All 78 113 2 68 3  
Age (years), Median (IQR) 47 (41–56) 60 (52–65) 65 (63–66) 56 (50–62) 58 (50–65) <0.001
BMI (kg/m2), Median (IQR) 21 (19–23) 23 (29–54) 26 (25–27) 22 (19–24) 22 (21–23) <0.001
No. of LN, Median (IQR) 39 (29–45) 43 (29–54) 53 (51–54) 44 (34–58) 31 (25–46) 0.038
Extent of lymphadenectomy
 PLA, N (%) 22 (28.2) 15 (13.3) 0(0) 5 (7.4) 1 (33.3) 0.006
 PLA + PALA, N (%) 56 (71.8) 98 (86.7) 2 (100) 63 (92.6) 2 (66.7)
LN metastasis
 Positive, N (%) 11 (14.1) 9 (8) 1 (50) 10 (14.7) 0 (0) 0.196
 Negative, N (%) 67 (85.9) 104 (92) 1 (50) 58 (85.3) 3 (100)
Retroperitoneal suture
 Yes, N (%) 58 (74.4) 82 (72.6) 2 (100) 57 (83.8) 3 (100) 0.372
 No, N (%) 20 (25.6) 31 (27.4) 0 (0) 11 (16.2) 0 (0)
Radiation therapy
 Yes, N (%) 12 (15.4) 5 (4.4) 0 (0) 0 (0) 0 (0) 0.003
 No, N (%) 66 (84.6) 108 (95.6) 2 (100) 68 (100) 3 (100)
Chemotherapy
 Yes, N (%) 53 (67.9) 67 (59.3) 2 (100) 58 (85.3) 2 (66.7) 0.002
 No, N (%) 25 (32.1) 46 (40.7) 0 (0) 10 (14.7) 1 (33.0)
Herbal medicine
 Yes, N (%) 2 (2.6) 5 (4.4) 0 (0) 3 (4.4) 0 (0) 0.872
 No, N (%) 76 (97.4) 108 (95.6) 2 (100) 65 (95.6) 3 (100)
Self-management education
 Yes, N (%) 36 (46.2) 57 (50.4) 1 (50) 26 (38.2) 0 (0) 0.266
 No, N (%) 42 (53.8) 56 (49.6) 1 (50) 42 (61.8) 3 (100)
Infection
 Skin (cellulitis), N (%) 4 (5.1) 9 (8.0) 0 (0) 3 (4.4) 0 (0) 0.809
 Lymphocyst, N (%) 3 (3.8) 6 (5.3) 0 (0) 6 (8.8) 0 (0)
 No, N (%) 71 (91.0) 98 (86.7) 2 (100) 59 (86.8) 3 (100)
Lymphocyst formation
 Yes, N (%) 23 (29.5) 37 (32.7) 1 (50) 32 (47.1) 0 (0) 0.095
 No, N (%) 55 (70.5) 76 (67.3) 1 (50) 36 (52.9) 3 (100)
No. of patients excluded owing to their medical history
 Before surgery 0 0 1 2 0  
 After surgery 0 4 0 2 0
  1. Definition of abbreviations: IQR Interquartile range, BMI Body mass index, No. Number, LN Lymph node, PLA Pelvic lymphadenectomy, PALA Para-aortic lymphadenectomy